bad news

Catalyst came early... We're closing down orders tomorrow at midnight Spots could be full as soon as tomorrow. More than half full The Project Greenlight Summit is LIVE right now! The Project Greenlight Summit is LIVE right now! — Dear Reader, Sorry it's so late, but I just got a text from Jason. The stock he mentioned to me in last week's Project Greenlight Summit went nuts today. You see, the company got an FDA drug approval and popped. Readers who signed up last week are sitting on a pretty nice little gain. During the interview, he mentioned a catalyst date of November 29th for this stock. But that's the LATEST that it was going to take place. This one came a bit early (as it sometimes does). I was REALLY hoping you'd get in on this play before the catalyst, but that did not happen. All is not lost though, because there are still 23 slots left in Jason's [Topline Trader service.]( If you’ve ever dreamed of living life on your own terms... Walking out of your job and never looking back... Having the time and financial freedom to spend your days playing golf... Pursuing your favorite hobbies... And never having to scrimp and save during retirement... Then becoming a member of [Topline Trader]( could be the best decision you EVER make. The moment you join, you’ll get 100% unlimited access to [Project Greenlight.]( That means six HIGHLY PROFITABLE biotech plays every single month... JUST like the one that went down today. Want to make hundreds of thousands — maybe even millions — off biotech? Don't miss out on the next play! [Click here to secure your spot.]( Here's to profits, Dave Roberts Vice President, Angel Publishing --------------------------------------------------------------- If you no longer wish to receive updates from Project Greenlight you [may opt out here.]( Project Greenlight, Copyright ©2019, Angel Publishing, LLC., 111 Market Place #720, Baltimore, MD 21202. For Customer Service, please call (877) 303-4529. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Angel Publishing and Project Greenlight does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this newsletter. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law.